一种强效和狭窄谱的抗菌药物,用于抗 Clostridioides difficile感染
Yuanyuan Qian1, Biruk T Birhanu1, Jingdong Yang1
1Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, United States.
Journal of medicinal chemistry
|September 21, 2023
概括
新的氧迪亚醇抗生素显示出对Clostridioides difficile (C. difficile) 的强烈杀菌活性. 这种窄谱化合物选择性地向C. difficile,为复发性C. difficile感染 (CDI) 提供了潜在的新疗法.
科学领域:
- 微生物学 微生物学
- 药用化学 医学化学
- 传染性疾病 传染性疾病
背景情况:
- 困难性闭塞杆菌 (C. difficile) 在25%的患者中引起复发性感染 (CDI),原因是由于广泛抗生素的肠道失生症.
- 现有的抗生素对多次复发的CDI发作不完全有效.
- 对于针对C. difficile的新型治疗药物有着至关重要的需求.
研究的目的:
- 识别和描述具有针对C. difficile的杀菌活性的新型氧化化合物.
- 评估有前途的氧沙醇类别的活性和选择性的范围.
- 为了研究最强效的化合物的作用机制.
主要方法:
- 对75个氧化醇的库进行选,以防C. difficile ATCC 43255.5.
- 合成和测试了58种额外的氧沙类比物.
- 对101种C. difficile菌株的最小抑制度 (MIC50和MIC90) 的确定.
- 对常见肠道细菌和其他微生物的活性评估.
主要成果:
- 鉴定出一种强效和狭窄谱的氧迪亚,化合物57 (3-(4-(cyclopentyloxy) phenyl) -5-5-(4-nitro-1H-imidazol-2-yl) -1,2,4-oxadiazole) 的存在.
- 化合物57对C. difficile表现出强烈的活性,MIC50=0.5μg/mL和MIC90=1μg/mL.
- 该化合物对C. difficile具有选择性的杀菌活性,对常见的肠道细菌或其他测试生物没有活性.
- 发现化合物57可以向C. difficile的细胞壁合成.
结论:
- 奥克萨迪亚醇抗生素对C. difficile具有显著的杀菌活性.
- 化合物57是开发新疗法治疗C. difficile感染的有希望的首选药物.
- 化合物57的狭窄光谱和选择性使其成为一个有吸引力的治疗选择,可能最大限度地减少对肠道微生物群的破坏.
相关概念视频
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
143
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
143
Antimicrobial Effectiveness
37
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
37
Drugs for Treatment of Diarrhea-Predominant IBS
200
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
200
Combined Effects of Drugs: Synergism
4.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.0K
Drugs for Treatment of Constipation-Predominant IBS
197
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
197
Antibiotic Selection
54.6K
Overview
54.6K


